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Abstract: Mucus is the first biological component inhaled drugs encounter on their journey towards 
their pharmacological target in the upper airways. Yet, how mucus may influence drug disposition 
and efficacy in the lungs has been essentially overlooked. In this study, a simple in vitro system was 
developed to investigate the factors promoting drug interactions with airway mucus in 
physiologically relevant conditions. Thin layers of porcine tracheal mucus were prepared in 
Transwell® inserts and initially, the diffusion of various fluorescent dyes across those layers was 
monitored over time. A deposition system featuring a MicroSprayer® aerosolizer was optimized to 
reproducibly deliver liquid aerosols to multiple air-facing layers and then exploited to compare the 
impact of airway mucus on the transport of inhaled bronchodilators. Both the dyes and drugs tested 
were distinctly hindered by mucus with high logP compounds being the most affected. The 
diffusion rate of the bronchodilators across the layers was in the order: ipratropium ≈ 
glycopyronnium > formoterol > salbutamol > indacaterol, suggesting hydrophobicity plays an 
important role in their binding to mucus but is not the unique parameter involved. Testing of larger 
series of compounds would nevertheless be necessary to better understand the interactions of 
inhaled drugs with airway mucus. 
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1. Introduction 
Development efforts in pulmonary drug delivery have primarily focused on advancing device 
technologies and formulations in order to improve aerosol deposition in the respiratory system as 
well as patients’ compliance [1]. Despite progresses in this field, no superior treatment of respiratory 
diseases by the inhaled route has been achieved in recent years and the attrition rate of inhaled drug 
candidates remains extremely high as compared to compounds developed for other therapeutic areas 
[2]. One of the principal underlying causes is a lack of understanding of the factors affecting drug 
disposition post-deposition in the lungs. Notably, very little is currently known on the interactions 
of inhaled drugs with the respiratory mucosa. 
In the upper airways, the epithelium is covered by a ~10 μm thick mucus layer that aerosolized 
drugs must be able to traverse for exerting their pharmacological action as well as avoiding rapid 
clearance by the mucocilliary escalator. Mucus has been demonstrated to act as a permeability barrier 
for a range of drugs, particularly lipophilic ones, and is thus deemed to affect their efficacy [3,4]. Due 
to the popularity of the oral route of administration, investigations on mucus–drug interactions have 
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nevertheless almost exclusively been performed using gastro-intestinal mucus [4] which exhibits 
different rheological characteristics from tracheal mucus [5], likely because of variations in their 
constitutive mucins and matrix organization [4]. Furthermore, study protocols have typically 
involved 400 μm to several mm thick mucus layers exposed to relatively large volumes of drug 
preparations to reproduce conditions in the gastro-intestinal tract [6,7]. Such experimental designs 
are not pertinent to aerosolized drugs which, in the clinic, directly land onto the airway mucosa. 
Considering the mucus layer is the first biological component encountered by inhaled drugs in 
the upper airways, it is surprising that very few studies so far have evaluated the impact of airway 
mucus on drug absorption in the lungs. In the 1990s, the permeability of the model antibiotics p-
aminosalicylic acid, isoniazid, and pyrazinamide was compared through a buffer solution, cystic 
fibrosis mucus, and pig gastric mucus [8]. Mucus secretions retarded the diffusion of all three drugs 
with the disease model having the greatest impact due to its higher viscosity. However, in that early 
work, the donor compartment of the diffusion system contained a non-physiologic large volume of 
drug solution. Two decades later, the permeation of gentamicin sulfate [9] and ketoprofen lysinate 
[10] formulated as inhalation dry powders was reported to be significantly delayed in modified Franz 
cells when these incorporated a layer of artificial cystic fibrosis mucus or cystic fibrosis sputum, 
respectively. A common limitation of the three aforementioned studies is that the thickness of the 
mucus layers (~3 mm) was not clinically representative. Recently, our group developed a more 
physiologically realistic in vitro model featuring ∼100 μm thick layers of porcine tracheal mucus 
formed at the surface of semi-permeable Transwell® cell culture inserts [11]. Salbutamol sulfate or 
indomethacin inhalation powders were then sprayed onto the mucus layers using a custom-made 
deposition system. Interestingly, mucus hindered salbutamol transport but enhanced that of 
indomethacin, suggesting it promoted the dissolution of poorly water soluble drugs such as 
indomethacin. 
Herein, we intended to apply drugs onto mucus layers as solution aerosols in order to 
differentiate the effect of airway mucus on drug diffusion from its role on particle solubilisation. 
Several sophisticated devices such as the CULTEX® [12], VITROCELL® [13], or ALICE-CLOUD 
[14,15] systems have been employed to directly expose cell culture models of the airway epithelium 
to aerosolized droplets. However, they necessitate technical expertise and generate low-dose 
prolonged exposures that are more suited to environmental toxicology studies than to drug transport 
measurements. In contrast, the MicroSprayer® IA-1C aerosolizer that was initially developed to 
facilitate the intratracheal administration of nebulized drugs in laboratory animals is straightforward 
to operate, only requires small volumes of drug formulations and delivers bolus doses alike 
therapeutic aerosols. Accordingly, it has successfully been used to expose cell cultures to aerosolized 
liquids [13,16–18]. The spray generated by the MicroSprayer® has typically been directed towards 
one single cell layer. Lengthy experiments were then required to obtain a satisfactory number of 
replicates. Furthermore, in such configuration, cells might be damaged by the power of the spray and 
exposed to doses that are much higher than in a clinical scenario. 
The overarching aim of this study was to develop a simple in vitro system to investigate the 
parameters affecting compound interactions with airway mucus in physiologically relevant 
conditions. We first evaluated the retardation effect of layers of porcine tracheal mucus mounted on 
Transwell® inserts on the permeation of a range of fluorescent dyes with various physico-chemical 
properties. We then optimized a deposition system based on the MicroSprayer® aerosolizer to 
simultaneously and reproducibly expose multiple biological layers to solution aerosols and applied 
this to determine the impact of airway mucus on the diffusion of inhaled bronchodilators. The 
compounds tested exhibited various permeation profiles across the mucus layers with 
hydrophobicity appearing as the predominant but not the sole factor driving their affinity towards 
airway secretions. 
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2. Materials and Methods 
2.1. Materials 
Transwell® inserts (1.2 mm diameter) and well plates were purchased from Corning Ltd 
(Loughborough, UK). Indacaterol maleate was purchased from MedChemExpress (MCE®, 
Monmouth Junction, NJ, USA). Formic acid and HPLC grade solvents for sample analysis were 
purchased from Fisher Scientific (Loughborough, UK). HPLC grade water was produced with a 
Purelab Ultra ELGA water purification system (Veolia Water Solutions and Technologies, 
Birmingham, UK). Unless specified, all other chemicals and reagents were obtained from Sigma-
Aldrich (Poole, UK). 
2.2. Coating of Transwell® Inserts with Porcine Tracheal Mucus 
Mucus was collected from the trachea of healthy adult pigs slaughtered at a local abattoir, 
cleared of blood contaminants and stored at −20 °C as previously described [11]. Freezing has been 
demonstrated to affect neither the viscoelastic properties of native mucus nor drug coefficient of 
diffusion across mucus models [19]. After thawing, 12 µL of mucus were resuspended in 0.1 M NaCl 
to reach a final volume of 300 µL. Twelve microliters were previously found to be the lowest volume 
of mucus providing full coverage of the Transwell® membrane [11]. The mucus suspension obtained 
was pipetted into Transwell® inserts housed in 12-well cell culture plates. The plates were centrifuged 
at 1500 rpm for 15 min; the supernatant were removed and 500 µL of Hank’s Balanced Salt Solution 
(HBSS) were placed into the wells. The plates were stored overnight to allow the mucus to stabilize 
and excess water to evaporate. 
2.3. Permeation of Fluorescent Dyes across Mucus Layers 
Mucus layers were formed at the surface of 0.4 μm pore size polyester Transwell® membranes 
as described above. Solutions (100 µM) of the fluorescent dyes Lucifer yellow CH dipotassium, 
Rhodamine B, Rhodamine 123, and Rose Bengal were prepared in HBSS while fluorescein 
isothiocyanate (FITC, 10 µM) was dissolved in HBSS containing 0.1% dimethyl sulfoxide (DMSO). 
Fifty µL of each dye solution pre-warmed to 37 °C were added to the apical chamber of bare inserts 
or inserts supporting a mucus layer and 500 µL of fresh pre-warmed HBSS (or HBSS + 0.1% DMSO 
in experiments with FITC) were added to the basolateral chamber. Samples (200 µL) were withdrawn 
from the basolateral side at pre-determined time points and replaced with 200 µL of fresh pre-
warmed HBSS/HBSS + 0.1% DMSO. The plate containing the Transwell® inserts was maintained at 37 
°C on an orbital shaker (60 rpm) between sampling times. One hundred µL of each withdrawn sample 
were transferred to a black 96-well plate (Nunc F96, Scientific Laboratory Supplies, Nottingham, UK) 
for fluorescence measurements using a Tecan (SPARK 10M) plate-reader (Lucifer yellow: λex = 427 
nm and λem = 535 nm; FITC: λex = 490 nm and λem = 540 nm; Rhodamine B: λex = 544 nm and λem = 680 
nm; Rhodamine 123: λex = 540 nm and λem = 590 nm; Rose Bengal: λex = 549 nm and λem = 620 nm). The 
dye concentration in the samples was determined from calibration curves prepared in HBSS or 
HBSS/0.1% DMSO (FITC). Experiments were performed across four mucus layers or empty 
Transwell® inserts (n = 4). In addition, FITC transport was assessed using four different batches of 
mucus (N = 4; n = 4). 
2.4. Optimization of the Aerosolization System 
In order to deposit aerosolized drug solutions at the surface of the mucus layers, a 
MicroSprayer® Aerosoliser Model IA-1C (Penn-Century. Inc. Wyndmoor, PA, USA) was mounted in 
a vacuum glass desiccator featuring an internal deposition surface (diameter: 18.4 cm) positioned 20.0 
cm below the port entrance (Figure 1). The air-free atomizer of the MicroSprayer® was secured inside 
a stopper and held in a vertical position facing the centre of the internal surface thanks to a custom-
made external stand. Dose volume “spacers” (25 or 50 µL) were attached to the plunger of the high-
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pressure syringe to facilitate precise delivery of defined volumes of aerosolised solutions. To ensure 
the production of a uniform aerosol spray, the plunger was actuated in a sharp and firm motion. 
 
Figure 1. Schematic representation of the deposition system. 
The semi-permeable membrane of four Transwell® inserts was covered with clean glass 
coverslips (1.2 cm in diameter, VWR, Lutterworth, UK) and those were placed inside Petri dish lids. 
The inserts were arranged on the internal glass desiccator surface to occupy the four corners (A, B, C, 
and D) of a virtual square centered below the tip of the MicroSprayer® and covering a surface of 20, 
50, or 100 cm2. A solution of Lucifer yellow (1 mM in HBSS) was loaded into the Penn-Century high-
pressure syringe and various volumes (50, 100, and 200 µL) were then sprayed inside the desiccator 
chamber. One hundred µL of HBSS were added to each Transwell®, 70 µL were collected back from 
each insert and transferred to a black 96 well plate for fluorescence reading. Experiments were 
performed in triplicate for each volume sprayed and geometrical arrangement (N = 3). 
2.5. Permeation across Mucus Following Aerosol Deposition 
The transport of Lucifer yellow and various bronchodilators across mucus layers spread at the 
surface of 0.4 or 3.0 μm pore size polyester Transwell® membrane was assessed and compared to their 
diffusion in corresponding empty inserts. 
The MicroSprayer® was loaded with Lucifer yellow (1 mM), ipratropium bromide, 
glycopyrronium bromide, salbutamol sulphate (all three drugs at a final concentration of 10 mM) 
dissolved in HBSS or formoterol and indacaterol maleate solutions (1 mM) prepared in HBSS with 
10% of DMSO. A volume of 200 µL was sprayed onto mucus covered or empty Transwell® inserts 
displayed according to the 50 cm2 geometrical arrangement described above. The inserts were 
immediately transferred to a 12-well plate and each well was filled with 500 µL of HBSS ± 10% DMSO 
depending on the test compound. The plate was incubated at 37 °C on an orbital shaker and samples 
(50 µL) were withdrawn from the basolateral chambers after pre-determined time points. Each 
sample was replaced with an equivalent volume of HBSS (±10% DMSO). 
Following the last sampling time point, the apical chamber was washed using 200 µL of HBSS 
(±10% DMSO) for quantification of the residual non-permeated test compound. The washed mucus 
layers were collected, vortexed for one minute, then centrifuged at 14,000 rpm for 5 min and the 
supernatants were sampled for drug content analysis. The amount of test compound detected in the 
wash samples was added to the cumulative amount recovered in the basolateral chamber to estimate 
the dose deposited onto the mucus layers or semi-permeable membranes upon aerosolisation of the 
test solutions. 
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Lucifer yellow concentrations were determined through fluorescence measurements while drug 
samples were analyzed by LC-MS/MS. 
Experiments were performed in triplicate (Lucifer yellow) or quadruplicate (bronchodilators) 
using four Transwell® inserts per replicate (n = 4). 
2.6. Drug Sample Analysis 
Samples obtained from the drug permeation experiments were analyzed by LC-MS/MS. 
The LC system comprised an Agilent Hewlett Packard series 1100 coupled with a Micromass 
Quattro Ultima Pt mass spectrometer (Waters, Milford, MA, USA) equipped with an electrospray ion 
source operated in positive mode. An ACE3 C18 (3 µm, 150 mm × i.d. 2.1 mm) column fitted with a 
C18 guard cartridge was used for all analysis. 
Ipratropium bromide, glycopyrronium bromide, formoterol, and indacaterol maleate were 
processed similarly. All samples were diluted 1:3 with cold methanol containing 5 nM of the internal 
standard (glycopyrronium bromide, ipratropium bromide, indacaterol maleate, and formoterol, 
respectively) before being stored overnight at −20 °C. The samples were vortexed for one minute and 
centrifuged at 5000 rpm for five minutes at 4 °C. The supernatants were diluted (1:1) with 0.1% formic 
acid in water, transferred to LC-MS vials and stored in a refrigerator until analysis. 
On the day of analysis, a 10 µL volume was injected into the LC-MS system. Samples were run 
at 0.2 mL/min applying a phase gradient, where phase A consisted of MilliQ water containing 0.1% 
formic acid and phase B consisted of methanol containing 0.1% formic acid. The gradient started at 
45% of phase B, then increased to 90% over two minutes before returning to 45% over 3.5 min and 
being maintained at that level until the end of the 8.5 min run time. A source temperature of 125 °C, 
a desolvation temperature of 350 °C and a collision energy of 28 kV (ipratropium and 
glycopyrronium), 18 kV (formoterol) or 30 kV (indacaterol) were applied. 
Salbutamol sulphate samples were diluted 1:1 with methanol, vortexed for a minute and 
centrifuged at 5000 rpm for five minutes at 4 °C. The supernatant were diluted 1:1 with phase A 
which consisted of an aqueous solution containing 0.1% v/v formic acid and ammonium formate 20 
mM (pH 3.8). 50 µL of the resulting solution was injected into the LC-MS/MS system for 
quantification. Samples were run at 0.2 mL min−1 isocratically using a 50:50 mixture of phase A and 
methanol as the mobile phase. The source temperature was set at 125 °C, the desolvation temperature 
was fixed at 350 °C and the collision energy applied was 20 kV. 
2.7. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6.02. Unpaired t-tests (multiple 
comparisons) and ANOVA two-way analysis (with Tukey’s multiple comparison tests) were used to 
compare data between two groups or more than two groups, respectively. Differences between 
experimental groups were considered significant when a p-value lower than 0.05 was obtained. 
3. Results and Discussion 
Due to the complexity of the lung anatomy, bio-relevant in vitro respiratory models are 
necessary to gain a deeper understanding of the parameters influencing the disposition of inhaled 
drugs following their deposition onto the airway mucosa. Mucus-drug interactions are particularly 
difficult to investigate in vivo, which incentivizes us to develop a model of airway mucus based on 
thin layers of native porcine tracheal mucus coating the semi-permeable membrane of Transwell® 
inserts [11]. Pig mucus was used as it is similar to human mucus [20] and more readily accessible. In 
our previous study, we showed that our pig tracheal mucus samples exhibited similar rheological 
properties and internal structure as those reported for human airway secretions [11]. 
Porcine tracheal mucus has previously been used to assess the muco-penetrative properties of 
drug nanocarriers designed for the inhaled route [21]. On the other hand, its effect on the permeation 
of small molecules has not been investigated, at the exception of our recent study on inhalation dry 
powders [11]. In the present work, we assessed the role of compound physico-chemical 
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characteristics on their permeation through porcine tracheal mucus layers, adapted our previously 
described deposition system [11] for production of liquid aerosols and exploited this to study the 
interactions of inhaled bronchodilators with airway secretions. 
3.1. Impact of Airway Mucus on the Permeation of Fluorescent Dyes 
We recently reported that mucus delayed the transport of the positively charged water soluble 
bronchodilator salbutamol but, in contrast, facilitated that of the negatively charged poorly soluble 
anti-inflammatory agent indomethacin after both drugs were exposed to the mucus layers as solid 
particle sprays using a bespoke deposition system [11]. As earlier studies with gastro-intestinal 
mucus had reported stronger binding for lipophilic molecules [3], our indomethacin data were not 
anticipated. They were nevertheless attributed to solubilisation enhancement properties of mucus 
and/or charge repulsion between the drug and the negatively charged mucin fibers. It is nevertheless 
possible that factors promoting compound interactions with mucus are dependent on the regional 
origin of the secretions. Mucus from different parts of the body are indeed well known to vary in 
mucin structure and scaffold organization [4]. 
Therefore, we measured the diffusion of diverse fluorescent dyes encompassing a broad range 
of physico-chemical properties across our mucus layers or empty Transwell® inserts in an attempt to 
uncover the molecular characteristics that might promote binding to airway mucus. Five dyes were 
selected for the study: Rhodamine B, a polar (logP: −1.1) amphoteric molecule; Rhodamine 123, a 
relatively hydrophilic (log P: 1.5) weak base that is partially ionized at pH 7.4 and three negatively 
charged dyes of increasing hydrophobicity; i.e., Lucifer yellow (logP: 2.6); FITC (logP: 4.5) and Rose 
Bengal (logP > 6). In this initial set of experiments, dye solutions were pipetted onto the layers to 
reflect protocols applied in related studies with gastro-intestinal mucus. Due to its poor solubility in 
water, DMSO was required to prepare solutions of FITC. However, the solvent did not to affect 
transport across the mucus layers when applied at a concentration up to 10% (Supplementary 
Materials, Figure S1). The reproducibility of the mucus samples was assessed by measuring FITC 
permeability across layers prepared from four different batches of mucus. The four separate 
permeation profiles of the dye were identical (Figure 2D, p > 0.05), demonstrating the reliability of 
the model. 
The presence of a mucus layers at the surface of the Transwell® inserts had distinct effects on the 
diffusion of the dyes into the basolateral chamber over time. Mucus had minimal impact on the 
permeation of Rhodamine B with only a slight retardation effect detected over the first 30 min of 
transport (Figure 2A, p < 0.05) and over 95% of the dose applied recovered in all receiver 
compartments after 120 min (Figure 2A, p > 0.05). The permeation profiles of Rhodamine 123 
with/without mucus were identical over the first 40 min (Figure 2B, p > 0.05). Thereafter, small but 
significant differences emerged (Figure 2B, p < 0.05) and by the end of the experiment, 90 ± 4 (SD)% 
of the dye had permeated the mucus vs 99 ± 1 (SD)% for bare inserts (p < 0.05). In the case of Lucifer 
yellow, a ∼10% lower diffusion across mucus was observed over its entire permeation profile (Figure 
2C, p < 0.05), which resulted in 88 ± 7 (SD)% of the dose transported within 2 h as compared to 98 ± 2 
(SD)% across empty inserts. FITC transport was more dramatically impaired by mucus as only 36 ± 
4 (SEM)% of the initial dose permeated through the layers in 120 min while 92 ± 2 (SEM)% was able 
to cross the semi-permeable membrane of the Transwell® over the same period of time (Figure 2D, p 
< 0.05 at all sampling points). Similarly, mucus markedly delayed the diffusion of Rose Bengal in the 
receiver chamber, reducing its permeation over 2 h from 99 ± 3 (SD)% to 43.7 ± 0.7 (SD)% of the donor 
dose (Figure 2E, p < 0.05 at all sampling points). 
Despite the small number of molecules tested, hydrophobicity stood out as a key parameter 
driving compound interactions with airway mucus while charge had much less of an impact. This is 
in line with the inverse relationship previously obtained between drug diffusion coefficients in native 
intestinal pig mucus and their lipophilicity as well as the minor role of compound charge in mucus 
binding observed in that model [22]. In contrast, no correlation between transport rate and log D was 
found in purified pig gastric mucin [22]. It was later demonstrated that hydrophobic interactions 
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occur preferentially with the lipids contained in raw intestinal pig mucus samples rather than with 
mucin itself [23]. 
 
Figure 2. Permeation profiles of fluorescent dyes across mucus layers spread at the surface of 0.4 µm 
pore size polyester Transwell® inserts and corresponding empty inserts. 50 µL of the dye solutions 
were added to the apical chambers at t = 0. A: Rhodamine B; B: Rhodamine 123; C: Lucifer yellow; D: 
FITC; E: Rose Bengal. Data are expressed as cumulative percentage of the initial donor dose recovered 
in the basolateral compartment as a function of time. They are presented as mean ± SD (n = 4) or mean 
± SEM (FITC; N = 4, n = 4). 
The high concentration of lipids found in intestinal mucus, e.g., 37% in dry weight [23], is often 
attributed to digested food. Nevertheless, human airway mucus has also been shown to include a 
high lipidic fraction, i.e., 25–40% in dry weight depending on the sample [24]. Lipids were very likely 
present in our mucus model since only a cleaning step to remove blood contaminants was carried out 
during the preparation of the Transwell®-supported layers. Binding to lipids was therefore the most 
probable mechanism underlying the marked effect of pig tracheal mucus on the permeability of FITC 
and Rose Bengal, the two highly hydrophobic dyes tested in this study (Figure 2). 
Our data suggests that low molecular weight compounds might interact with airway or gastro-
intestinal mucus in a similar fashion. It would however be interesting to compare the permeation of 
the same series of molecules across both tracheal and gastro-intestinal mucus in identical diffusion 
systems. This would also indicate whether airway mucus offers any benefit in inhaled drug 
permeation studies or alternatively, could be substituted by gastro-intestinal mucus whose yield per 
animal is much higher than that of tracheal secretions. 
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3.2. Optimization of the Aerosolization System 
In order to mimic the clinical situation, aerosolized drugs must be directly deposited onto any 
in vitro model of the airway mucosa. To achieve this, our previously described deposition system 
was modified by replacing the PennCenturyTM Dry Powder Insufflator [11] with a MicroSprayer® 
Aerosoliser to allow the exposure of air-facing mucus layers to liquid aerosols. In order to minimize 
the physical impact of the liquid sprays on the mucus model, four Transwell® inserts were positioned 
20 cm below the tip of the Aerosoliser and at variable distance from the centre of the spray in an 
arrangement shaping a squared area of either 20, 50, or 100 cm2 (Figure 3). The extent and 
reproducibility of the dose delivered onto the inserts was optimized by spraying different volumes 
of Lucifer yellow solutions inside the aerosolization chamber. 
 
Figure 3. Doses of Lucifer yellow deposited on Transwell® inserts when sprayed from a distance of 
20 cm. Inserts were arranged to cover a 20 (A), 100 (B), or 50 (C) cm2 surface area. Data are presented 
as mean ± SD (n = 3). 
As expected, for all geometric configurations, a spray volume of 200 µL resulted in a higher 
average amount of fluorescent dye delivered to the inserts than a spray of 50 or 100 µL (Figure 3). 
When the inserts were placed at the shortest distance from the center of the deposition platform, they 
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received highly variable doses of the dye with any of the three volumes of Lucifer yellow aerosolized 
(coefficient of variation up to 72%) (Figure 3A). Positioning the Transwell® inserts at the outskirts of 
the deposition chamber improved the reproducibly of the deposited dose and no significant 
difference was noted between the amount of dye reaching the four inserts when 100 µL of the solution 
was released from the MicroSprayer® (p > 0.05, Figure 3B). However, that amount was very low (<0.06 
nmol) and could have led to analytical challenges during permeation studies across the mucus layers. 
The intermediate geometric arrangement in which the inserts delineated a 50 cm2 square provided a 
compromise between efficient deposition and dose reproducibility. In that set-up, spraying a volume 
of 200 µL resulted in 0.12 ± 0.04 nmol (which corresponded to ~120 nL) of the fluorescent dye 
consistently landing onto the four Transwell® inserts (p < 0.05, Figure 3C). 
Applying those experimental conditions, Lucifer yellow was then sprayed onto mucus layers 
spread at the surface of the Transwell® inserts or into bare inserts and its diffusion into the basolateral 
compartment was monitored over 120 min. The transport of the aerosolized dye across both mucus 
and the semi-permeable membrane alone was initially faster than after addition of 50 μL of the dye 
solution into the donor chambers (Figure 2D). Indeed, after 10 min, 48% ± 5% of the deposited aerosol 
dose had diffused through air-interfaced mucus layers (Figure 4) as compared to 22% ± 4% (p < 0.05) 
when these were submerged by the dye solution (Figure 2D). Permeation across the bare Transwell® 
membrane was rapid with >90% of the dose recovered in the receiver chamber after 20 min (Figure 
4). This can probably be explained by the absence of a bulk solution and unstirred water layer acting 
as diffusion barriers upon direct exposure of the mucus or the semi-permeable membrane to the dye. 
However, the hindering effect of mucus on Lucifer yellow diffusion was more pronounced upon 
aerosolization of the dye, as indicated by the clear difference in its permeation profiles in presence or 
absence of airway secretions (Figure 4), unlike those across submerged mucus layers and Transwell® 
membranes (Figure 2D). In submerged conditions, mucus could have been diluted by the dye 
solution and would therefore have formed a rather lose layer at the surface of the Transwell® inserts 
allowing a freer diffusion of the solutes. This illustrates the importance of investigating drug 
interactions with biological barriers using in vitro systems that closely resemble the in vivo 
environment being modelled. 
 
Figure 4. Permeation profiles of Lucifer yellow after it was sprayed at a distance of 20 cm onto mucus 
layers prepared in 0.4 µm pore size polyester Transwell® inserts or corresponding empty inserts 
arranged to cover a 50 cm2 surface area. Data are expressed as cumulative percentage of the deposited 
dose recovered in the basolateral compartment as a function of time. They are presented as mean ± 
SEM (N = 3, n = 4). 
3.3. Interactions of Inhaled Bronchodilators with Airway Mucus 
The deposition system was then employed to evaluate the influence of airway mucus on the 
pulmonary absorption of marketed inhaled bronchodilators of the M3 antagonist (ipratropium and 
glycopyrronium) and β2-agonist classes (salbutamol, formoterol and indacaterol). Those drugs are 
either cationic or zwitterionic at neutral pH but significantly differ in their lipophilicity (Table 1). 
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The amounts deposited onto the mucus layers ranged from ∼200 to 700 ng and was more 
dependent on the drug itself than on the concentration of the solution loaded into the MicroSprayer® 
(Table 1). Those variations might be related to changes in the viscosity of the test solutions and the 
geometry of the spray with the investigated compounds. In a clinical scenario, if one considers 20–
50% of the dose emitted from the inhaler reach the lungs [25], a typical patchy drug distribution [25] 
and the surface area of the upper airways, the deposited dose per surface area is likely to be even 
lower. However, replicating such doses in vitro is not feasible as they would result in undetectable 
concentrations of permeated drugs. 
Ipratropium and glycopyrronium exhibited indistinguishable permeation profiles across the 
mucus layers with, respectively, 44% ± 4% and 48% ± 3% of the applied dose detected in the receiver 
chambers after the first five minutes and a plateau above 95% observed from 45 min onwards (Figure 
5A,B, p > 0.05). The permeation profile of both drugs then coincided with that across the empty 
Transwell® inserts (Figure 5A,B, p > 0.05). Those data were not surprising since the two M3 
antagonists share similar physicochemical properties such as a low logP value and the presence of a 
quaternary ammonium in their chemical structure (Table 1). 
Table 1. Properties, dose deposited and permeation rate through mucus layers of the bronchodilators 
tested. 
Compound Chemical Class 
LogP 
* 
MW 
* 
H-Bond 
(Donor/Acceptor) * Dose Deposited (ng) 
T50 a 
(min) 
T50 b 
(min) 
Ipratropium Quaternary −1.8 412 1/4 442 ± 76 7.0 ± 0.5 <5 
Glycopyronnium Quaternary −1.4 398 1/4 384 ± 92 5.4 ± 0.9 ND 
Salbutamol Base 1.4 577 10/12 687 ± 116 19 ± 3 12.4 ± 0.8 
Formoterol Base 2.2 344 4/5 216 ± 46 13 ± 3 7 ± 1 
Indacaterol Zwitterion 4.05 509 6/8 232 ± 61 67 ± 11 20 ± 1 
* extracted from PubChem (https://pubchem.ncbi.nlm.nih.gov); MW: molecular weight; T50: time 
taken for 50% of the deposited dose to cross mucus layers mounted on a 0.4 μm or b 3.0 μm pore size 
inserts; ND: not determined; Data are presented as mean ± SEM (N = 4, n = 4). 
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Figure 5. Permeation profiles of inhaled bronchodilators after they were sprayed at a distance of 20 
cm onto mucus layers mounted onto 0.4 µm pore size polyester Transwell® inserts or corresponding 
empty inserts arranged to cover a 50 cm2 surface area. A: glycopyrronium bromide; B: ipratropium 
bromide; C: salbutamol sulphate; D: formoterol; E: indacaterol maleate. Data are expressed as 
cumulative percentage of the deposited dose recovered in the basolateral compartment as a function 
of time. They are presented as mean ± SEM (N = 4, n = 4). 
In contrast, the β2-agonists interacted differently with airway mucus. The diffusion of the short 
acting salbutamol was significantly lower across airway mucus than Transwell® inserts over all time 
points (Figure 5C, p < 0.05) and only 31 ± 3% of the initial dose had permeated the mucus layers within 
the first five minutes, confirming our previous observations that mucus impairs the pulmonary 
absorption of that inhaled drug [11]. The transport across airway secretions of the long-acting 
formoterol was faster than that of salbutamol. A higher percentage of the former drug, i.e., 39 ± 8% 
was recovered basolaterally five minutes post aerosolization and during the second hour of the study, 
the fractions that had diffused through the mucus or the bare inserts were not statistically different 
(Figure 5D, p > 0.05). Finally, a slow permeation across mucus was evident for the ultra-long-acting 
indacaterol (Figure 5E). While a similar amount of the drug as for salbutamol had crossed the layers 
within the first 5 min; i.e., 31 ± 6%, only two thirds of the applied dose of indacaterol was able to 
overcome the mucus barrier in 120 min (Figure 5E). 
In line with previous observations with the different fluorescent dyes, the highly hydrophobic 
bronchodilator indacaterol was strongly retained within the mucus layers despite its net neutral 
charge while the highly hydrophilic positively charged M3 antagonists showed the weakest 
interactions with mucus. Hydrophobicity can nevertheless not be accounted for the relatively slow 
permeation of salbutamol across airway mucus, suggesting additional drug properties promote 
mucus binding, such as for instance, their ability to form hydrogen bonds with mucus components. 
Salbutamol indeed features a very high number of hydrogen bond acceptor and donor sites as 
compared to the other inhaled drugs included in this study (Table 1), which could explain its 
interactions with mucus were stronger than expected based on its hydrophilicity. 
However, as a matter of concern, it was noticeable that the Transwell® membrane itself acted as 
a diffusion barrier to all five drugs but particularly to indacaterol (Figure 5). A similar rate-limiting 
diffusion across Transwell® inserts had previously been reported for the poorly water soluble inhaled 
corticosteroid ciclesonide as part of a drug dissolution study [26]. This was then corrected by 
replacing the 0.4 μm pore size polyester membranes of the Transwell® by glass microfiber or paper 
filters affixed onto the plastic walls of the inserts using mild heat [26]. As a more convenient 
alternative, herein, we replicated ipratropium, salbutamol, formoterol and indacaterol permeation 
studies with mucus layers mounted onto 3.0 μm instead of 0.4 μm pore size polyester Transwell®. 
Using those more porous inserts, at least 85% of the dose deposited onto the membrane was detected 
in the receiver chambers within the first 5 min for all four drugs tested (Figure 6). 
Transport across airway secretions was also less restricted than when the layers were supported 
by semi-permeable membranes with narrower pores, as reflected by a reduction in the time needed 
for 50% of the applied dose to diffuse into the basolateral compartments (T50, Table 1). The extent of 
increase in transport rate was however drug dependent. The difference in T50 was negligible for 
ipratropium but pronounced for indacaterol (Table 1), suggesting that molecular diffusion through 
the Transwell® membrane can be delayed due to hydrophobic interactions. Nevertheless, the four 
bronchodilators ranked in the same order in terms of diffusion rate across mucus in the two types of 
inserts; i.e., ipratropium > formoterol > salbutamol > indacaterol (Table 1), which indicates that mucus 
had overall a more significant impact on their permeation than the semi-permeable membrane. It is 
noteworthy that, in contrast to the pore size, the membrane material had a very limited influence on 
drug transport. Indeed, the permeation profiles of indacaterol with or without mucus in 
polycarbonate vs polyester Transwell® were comparable, although the drug was marginally more 
hindered in the former (Supplementary Materials, Figure S2). This is not surprising considering the 
two polymers exhibit close water contact angles; i.e., 84° for polycarbonate [27] and ~75° for 
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polyethylene terephthalate (PET, polyester) [28]. Accordingly, they are both considered as 
moderately hydrophilic with polycarbonate being slightly more hydrophobic. 
 
Figure 6. Permeation profiles of inhaled bronchodilators after they were sprayed at a distance of 20 
cm onto mucus layers mounted onto 3.0 µm pore size polyester Transwell® inserts or corresponding 
empty inserts geometrically arranged to cover a 50 cm2 surface area. A: ipratropium bromide; B: 
salbutamol sulphate; C: formoterol; D: indacaterol maleate. Data are expressed as cumulative 
percentage of the deposited dose recovered in the basolateral compartment as a function of time. They 
are presented as mean ± SEM (N = 4, n = 4). 
Overall, our data suggest that airway mucus could interfere with the absorption of inhaled 
bronchodilators in the lungs. The impact of mucus on drug diffusion may nevertheless be 
overestimated in this model. Indeed, the thickness of the mucus layers (~100 µm) was 10 fold that of 
the mucus blanket in vivo as it was not experimentally possible to form thinner supported mucus 
layers that covered the entire surface of the Transwell® membranes [11]. Furthermore, inhaled 
bronchodilators all show a very low permeability across bronchial epithelial cells in vitro [11,29–31] 
and we previously reported salbutamol transport was restricted to a larger extent by epithelial layers 
than by mucus [11]. Therefore, the airway epithelium likely represents the major barrier to absorption 
for those drugs in the lungs. Binding to the mucus layer could nevertheless enhance the retention of 
relatively hydrophobic inhaled drugs in the pulmonary tissue, although this would presumably be 
associated with a loss of therapeutic activity. 
4. Conclusions 
A simple deposition system was assembled to deliver reproducible doses of liquid aerosols to 
multiple Transwell® inserts. It was used in this work to explore the impact of airway mucus on the 
permeation of a series of inhaled bronchodilators in physiologically relevant conditions but would 
also be suitable for exposing air-interfaced respiratory cell culture models to aerosolized drugs and 
formulations. Airway mucus was shown to delay the diffusion of all tested drugs, although to various 
extents. The number of compounds included in the study was too small to establish reliable 
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correlations between physico-chemical properties and mucus affinity. Nevertheless, hydrophobicity 
emerged as one important factor. The involvement of additional drug characteristics was evident 
although defining these will require measuring the transport of larger series of compounds across 
airway mucus. This study indicates binding to mucus might affect the disposition and therapeutic 
activity of inhaled drugs in the lungs. Investigating their interactions with airway mucus is therefore 
worth pursuing, ideally using mucus from diseased rather than healthy lungs. 
Supplementary Materials: The following are available online at www.mdpi.com/1999-4923/12/2/145/s1,  
Figure S1: Effect of increasing concentrations of DMSO on solute transport across mucus layers, Figure S2: Effect 
of the Transwell® membrane composition on molecular diffusion. 
Author Contributions: Conceptualization, S.A. and C.B.; methodology, S.A.; software, not applicable.; 
validation, S.A., C.B., C.J.R., and S.S.; formal analysis, S.A. and C.B.; investigation, S.A.; resources, not applicable; 
data curation, S.A.; writing—original draft preparation, C.B.; writing—review and editing, S.A., C.J.R., and S.S.; 
visualization, S.A.; supervision, C.B., C.J.R., and S.S.; project administration, C.B., C.J.R., and S.S.; funding 
acquisition, S.A. All authors have read and agreed to the published version of the manuscript. 
Funding: S.A.’s scholarship was funded by Prince Sattam Bin Abdulaziz University, Saudi Arabia. This research 
received no other external funding. 
Acknowledgments: Catharine Ortori (School of Pharmacy, University of Nottingham) for her help with the 
analysis of the drug samples. 
Conflicts of Interest: The authors declare no conflict of interest. The funder had no role in the design of the 
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to 
publish the results. 
References 
1. Moon, C.; Smyth, H.D.C.; Watts, A.B.; Williams, R.O. 3rd. Delivery technologies for orally inhaled 
products: An update. AAPS PharmSciTech. 2019, 20, 117, doi:10.1208/s12249-019-1314-2. 
2. Barnes, P.J.; Bonini, S.; Seeger, W.; Belvisi, M.G.; Ward, B.; Holmes A. Barriers to new drug development 
in respiratory disease. Eur. Respir. J. 2015, 45, 1197–1207. 
3. Sigurdsson, H.H.; Kirch, J.; Lehr, C.M. Mucus as a barrier to lipophilic drugs. Int. J. Pharm. 2013, 453, 56–
64. 
4. Murgia, X.; Loretz, B.; Hartwig, O.; Hittinger, M.; Lehr, C.M. The role of mucus on drug transport and its 
potential to affect therapeutic outcomes. Adv. Drug Deliv. Rev. 2018, 15, 82–97. 
5. Bokkasam, H.; Ernst, M.; Guenther, M.; Wagner, C.; Schaefer, U.F.; Lehr, C.M. Different macro- and micro-
rheological properties of native porcine respiratory and intestinal mucus. Int. J. Pharm. 2016, 510, 164–167. 
6. Shaw, L.R.; Irwin, W.J.; Grattan, T.J.; Conway, B.R. The influence of excipients on the diffusion of ibuprofen 
and paracetamol in gastric mucus. Int. J. Pharm. 2005, 290, 145–154. 
7. Friedl, H.; Dünnhaupt, S.; Hintzen, F.; Waldner, C.; Parikh, S.; Pearson, J.P.; Wilcox, M.D.; Bernkop-
Schnürch, A. Development and evaluation of a novel mucus diffusion test system approved by self-
nanoemulsifying drug delivery systems. J. Pharm. Sci. 2013, 102, 4406–4413. 
8. Bhat, P.G.; Flanagan, D.R.; Donovan, M.D. Drug diffusion through cystic fibrotic mucus: Steady-state 
permeation, rheologic properties, and glycoprotein morphology. J. Pharm. Sci. 1996, 85, 624–630. 
9. Russo, P.; Stigliani, M.; Prota, L.; Auriemma, G.; Crescenzi, C.; Porta, A.; Aquino, R.P. Gentamicin and 
leucine inhalable powder: What about antipseudomonal activity and permeation through cystic fibrosis 
mucus? Int. J. Pharm. 2013, 440, 250–255. 
10. Stigliani, M.; Manniello, M.D.; Zegarra-Moran, O.; Galietta, L.; Minicucci, L.; Casciaro, R.; Garofalo, E.; 
Incarnato, L.; Aquino, R.P.; Del Gaudio, P.; et al. Rheological Properties of Cystic Fibrosis Bronchial 
Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate. J. Aerosol. Med. Pulm. 
Drug Deliv. 2016, 29, 337–345. 
11. Cingolani, E.; Alqahtani, S.; Sadler, R.C.; Prime, D.; Stolnik, S.; Bosquillon, C. In vitro investigation on the 
impact of airway mucus on drug dissolution and absorption at the air-epithelium interface in the lungs. 
Eur. J. Pharm. Biopharm. 2019, 141, 210–220. 
Pharmaceutics 2020, 12, 145 14 of 15 
 
12. Deschl, U.; Vogel, J.; Aufderheide, M. Development of an in vitro exposure model for investigating the 
biological effects of therapeutic aerosols on human cells from the respiratory tract. Exp. Toxicol. Pathol. 2011, 
63, 593–598. 
13. Fröhlich, E.; Bonstingl, G.; Höfler, A.; Meindl, C.; Leitinger, G.; Pieber, T.R.; Roblegg, E. Comparison of two 
in vitro systems to assess cellular effects of nanoparticles-containing aerosols. Toxicol. In Vitro 2013, 27, 409–
417. 
14. Brandenberger, C.; Mühlfeld, C.; Ali, Z.; Lenz, A.G.; Schmid, O.; Parak, W.J.; Gehr, P.; Rothen-Rutishauser, 
B. Quantitative evaluation of cellular uptake and trafficking of plain and polyethylene glycol-coated gold 
nanoparticles. Small 2010, 6, 1669–1678. 
15. Lenz, A.G.; Stoeger, T.; Cei, D.; Schmidmeir, M.; Semren, N.; Burgstaller, G.; Lentner, B.; Eickelberg, O.; 
Meiners, S.; Schmid, O. Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial 
cells cultured in air-liquid interface conditions. Am. J. Respir. Cell Mol. Biol. 2014, 51, 526–535. 
16. Blank, F.; Rothen-Rutishauser, B.M.; Schurch, S.; Gehr, P. An optimized in vitro model of the respiratory 
tract wall to study particle cell interactions. J. Aerosol. Med. 2006, 19, 392–405. 
17. Heuking, S.; Rothen-Rutishauser, B.; Raemy, D.O.; Gehr, P.; Borchard, G. Fate of TLR-1/TLR-2 agonist 
functionalised pDNA nanoparticles upon deposition at the human bronchial epithelium in vitro. J. 
Nanobiotechnol. 2013, 21, 29. 
18. Meindl, C.; Stranzinger, S.; Dzidic, N.; Salar-Behzadi, S.; Mohr, S.; Zimmer, A.; Fröhlich, E. Permeation of 
Therapeutic Drugs in Different Formulations across the Airway Epithelium In Vitro. PLoS ONE 2015, 
10,e0135690. 
19. Groo, A.C.; Lagarce, F. Mucus models to evaluate nanomedicines for diffusion. Drug Discov. Today 2014, 
19, 1097–1108. 
20. Kararli, T.T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and 
commonly used laboratory animals. Biopharm. Drug. Dispos. 1995, 16, 351–380. 
21. Murgia, X.; Pawelzyk, P.; Schaefer, U.F.; Wagner, C.; Willenbacher, N.; Lehr, C.M. Size-Limited Penetration 
of Nanoparticles into Porcine Respiratory Mucus after Aerosol Deposition. Biomacromolecules 2016, 17, 
1536–1542. 
22. Larhed, A.W.; Artursson, P.; Gråsjö, J.; Björk, E. Diffusion of drugs in native and purified gastrointestinal 
mucus. J. Pharm. Sci. 1997, 86, 660–665. 
23. Larhed, A.W.; Artursson, P.; Björk, E. The influence of intestinal mucus components on the diffusion of 
drugs. Pharm. Res. 1998, 15, 66–71. 
24. Slayter, H.S.; Lamblin, G.; Le Treut, A.; Galabert, C.; Houdret, N.; Degand, P.; Roussel, P. Complex structure 
of human bronchial mucus glycoprotein. Eur. J. Biochem. 1984, 142, 209–218. 
25. Fröhlich, E. Biological Obstacles for Identifying In Vitro-In Vivo Correlations of Orally Inhaled 
Formulations. Pharmaceutics 2019, 11, E316, doi:10.3390/pharmaceutics11070316. 
26. Rohrschneider, M.; Bhagwat, S.; Krampe, R.; Michler, V.; Breitkreutz, J.; Hochhaus, G. Evaluation of the 
Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane 
and Surfactant. Mol. Pharm. 2015, 12, 2618–2624. 
27. Jankowski, P.; Ogonczyk, D.; Kosinski, A.; Lisowski, W.; Garstecki, P. Hydrophobic modification of 
polycarbonate for reproducible and stable formation of biocompatible microparticles. Lab Chip 2011, 11, 
748–752. 
28. Jasmee, S.; Omar, G.; Masripan, N.A.B; Kamarolzaman, A.A; Ashikin, A.S.; Che Ani, F. Hydrophobicity 
performance of polyethylene terephthalate (PET) and thermoplastic polyurethane (TPU) with thermal 
effect. Mater. Res. Express 2018, 5, 096304. 
29. Mukherjee, M.; Pritchard, D.I.; Bosquillon, C. Evaluation of air-interfaced Calu-3 cell layers for 
investigation of inhaled drug interactions with organic cation transporters in vitro. Int J Pharm 2012, 426, 
7–14. 
30. Mukherjee, M.; Cingolani, E.; Pritchard, D.I.; Bosquillon, C. Enhanced expression of Organic Cation 
Transporters in bronchial epithelial cell layers following insults associated with asthma—Impact on 
salbutamol transport. Eur. J. Pharm. Sci. 2017, 106, 62–70. 
31. Panduga, V.; Stocks, M.J.; Bosquillon, C. Ipratropium is 'luminally recycled' by an inter-play between apical 
uptake and efflux transporters in Calu-3 bronchial epithelial cell layers. Int. J. Pharm. 2017, 532, 328–336. 
Pharmaceutics 2020, 12, 145 15 of 15 
 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
